Literature DB >> 2194093

Demonstration of RNA N-glycosidase activity of a Vero toxin (VT2 variant) produced by Escherichia coli O91:H21 from a patient with the hemolytic uremic syndrome.

M Furutani1, K Ito, Y Oku, Y Takeda, K Igarashi.   

Abstract

A new Vero toxin purified from Escherichia coli O91:H21 isolated from a patient with the hemolytic uremic syndrome (VT2vh) was shown to inhibit elongation factor 1-dependent aminoacyl-tRNA binding to ribosomes, resulting in inhibition of protein synthesis in rabbit reticulocytes. VT2vh, like Shiga toxin, VT1 and VT2, showed RNA N-glycosidase activity and cleaved the N-glycosidic bond of the adenosine residue at position 4324 in 28S ribosomal RNA.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2194093     DOI: 10.1111/j.1348-0421.1990.tb01019.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  3 in total

1.  A plant-based oral vaccine to protect against systemic intoxication by Shiga toxin type 2.

Authors:  Sharon X Wen; Louise D Teel; Nicole A Judge; Alison D O'Brien
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-25       Impact factor: 11.205

Review 2.  Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome.

Authors:  Saul Tzipori; Abhineet Sheoran; Donna Akiyoshi; Arthur Donohue-Rolfe; Howard Trachtman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

3.  Antibody recognition of Shiga toxins (Stxs): computational identification of the epitopes of Stx2 subunit A to the antibodies 11E10 and S2C4.

Authors:  Yongjun Jiao; Fiona S Legge; Xiaoyan Zeng; Herbert R Treutlein; Jun Zeng
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.